Catherine Novack

Joon Lee

Salim Syed

Jiale Song

Joseph Schwartz

Lisa Walter

Madison El-Saadi

Madison Wynne El-Saadi

Ron Feiner

Ananda Ghosh

Andrew Fein

Anthony

Cheng Li

Eric Joseph

Jenny Leigh Gonzalez-Armenta

Joe Schwartz

Luca Issi

Martin Auster

Nicholas Econom

Roger Song

Ryan Deschner

Samantha Semenkow

Steven Seedhouse

Steve Seedhouse

Tiago Fauth

Yun Jung

Yun Zhong

- WVE-006, a treatment for Alpha-1 Antitrypsin Deficiency (AATD), demonstrated a **favorable safety profile** across all tested doses and regimens in the Restoration 1 and 2 clinical trials, with all drug-related adverse events being mild to moderate in intensity.  **[1631574_tx_382747_2]** 
- In the Restoration 2 trial, WVE-006 showed efficient and durable RNA editing, with the 200 mg multi-dose cohort achieving a mean max MAAT protein proportion of around **64%** of total AAT.  **[1631574_tx_382747_3]** **[1631574_tx_382747_5]**  A single 200 mg dose also enabled a ZZ individual to produce a **dynamic AAT response** during an acute phase event, with serum total AAT increasing to over **20 micromolar**.  **[1631574_tx_382747_3]** **[1631574_tx_382747_4]** 
- The 400 mg single dose cohort achieved serum total AAT of **12.8 micromolar** and MAAT of **5.3 micromolar**, with circulating MAAT reaching **47.2%** of total AAT and ZAAT decreasing by **49%**.  **[1631574_tx_382747_4]** 
- The data supports **monthly or less frequent dosing** for WVE-006, with complete data from the 400 mg multiple-dose cohort expected in **Q1 2026**.  **[1631574_tx_382747_4]** **[1631574_tx_382747_9]** 
- Wave Life Sciences is eligible for substantial milestone payments of up to **$3.3 billion** from its collaboration with GSK, with anticipated payments in 2025 and beyond.  **[1631574_tx_382747_5]**

Wave Life Sciences provides WVE-006 clinical trial update

Wave Life Sciences (WVE)